- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PET/CT boosts classification of incidental adrenal masses
In what is possibly the largest study of its kind, Harvard University researchers have shown that PET/CT can reliably tell whether unsuspected adrenal lesions discovered while managing oncologic patients are benign or malignant.
In what is possibly the largest study of its kind, Harvard University researchers have shown that PET/CT can reliably tell whether unsuspected adrenal lesions discovered while managing oncologic patients are benign or malignant.
Incidental adrenal lesions in patients with cancer require accurate characterization because their status can significantly affect staging, therapy, and prognosis. Several imaging tests are available to offer a helping hand, including contrast/noncontrast CT and MRI. None, however, has proven conclusive.
A 2006 Massachusetts General Hospital study of 38 patients found PET/CT to be sensitive and specific for the characterization of incidental adrenal lesions (Blake MA, Slattery JM, Kalra MK. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 2006;238(3):970-977). The results encouraged an investigative group led by Dr. Giles W. L. Boland, an associate professor of radiology at Mass General, to validate the findings in a larger cohort of patients.
Between October 2004 and March 2007, Boland and colleagues evaluated 150 patients with various malignancies, including lymphoma and lung, head and neck, and colorectal cancer. All patients underwent noncontrast PET/CT and a follow-up CT scan six months later. The researchers confirmed that PET/CT was highly effective for differentiating benign from malignant adrenal disease in this patient population. Based on a qualitative analysis, PET/CT yielded sensitivity, specificity, accuracy, and positive and negative predictive values for characterization of benign adrenal "incidentalomas" of 100%, 97%, 98%, 87%, and 100%, respectively.
Boland cautioned the study had several limitations, including the retrospective nature of the sample. He called for careful consideration of many other criteria, including the Hounsfield unit and standardized uptake value measurements, adrenal wash-outs, and lesion size assessments. But the findings showed a way forward, he said.
"PET/CT is indeed an accurate test," Boland said.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
